21-11-2008Sandoz gets positive opinion for biosimilar filgrastim

Sandoz has received a positive opinion from European regulators for its third biosimilar medicine, filgrastim, marking another important milestone in its efforts to bring affordable high-quality biopharmaceuticals to patients worldwide.

20-10-2008Latest Results Q3 2008

Novartis delivers sustained strong performance in first nine months of 2008 underpinned by accelerating growth in pharmaceuticals

03-09-2008Sandoz receives FDA approval

for Omnitrope® Pen 10 with liquid cartridge

17-07-2008Latest Results - Q2 2008

Novartis gains momentum with strong performance in first half of 2008 from portfolio focused on growth areas of healthcare

13-05-2008International presentation of clinical safety and efficacy data for Binocrit®, the world’s first complex biosimilar

• - First international presentation of clinical evidence supporting a biopharmaceutical approved by the biosimilar regulatory process
• - Data demonstrate safety and efficacy of Binocrit® in anemia treatment
• - Sandoz further confirms pioneering position in biosimilars, enhancing patient access to high-quality, affordable biopharmaceuticals

30-04-2008Sandoz Receives Regulatory Guidance on Enoxaparin ANDA

Expects to Submit Amendment to ANDA in Third Quarter, 2008

21-04-2008Latest Results - Q1 2008

Novartis reports higher sales and earnings in first quarter of 2008 showing healthcare portfolio well on the way to new growth cycle

12-03-2008Sandoz enhances patient access with launch of Omnitrope™ Pen 5

- New delivery system enables patient convenience
- Priced 35% below the originator product, furthering patient access to Omnitrope, first follow-on version of a recombinant biotechnology drug

17-01-2008Novartis results 2007

Novartis achieves record results in 2007 underscoring benefits of strategic healthcare portfolio